Investor Centre

Pharmaxis (ASX: PXS) today announced that, on this occasion, its new drug for treating cystic fibrosis, Bronchitol, has not been recommended for listing on the Australian Pharmaceutical Benefits Scheme by the government’s expert advisory body, the Pharmaceutical Benefits Advisory Committee (PBAC). 

Pharmaxis has been verbally advised of the decision made at the Committee’s November meeting, the minutes of which will be published on the PBAC website next month.  Pharmaxis will meet with the Chair of PBAC in early December to discuss the outstanding concerns of the Committee.

Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe “for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care.” 

Pharmaxis Ltd (PXS) expects to receive definitive notification of the outcome of the re-examination of Bronchitol® for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time).  The Company therefore anticipates making an announcement concerning the re-examination by 8.30am Monday 24 October 2011.  That announcement will have the effect of ending the current voluntary suspension of the Company’s shares. 

The Company will hold an investor teleconference at 9.00am Monday 24 October to discuss the announcement.

Telephone access (toll free):
• Australia: 1800 558 698
• USA/Canada: 1877 642 9125
• UK: 0800 635 0664
• NZ: 0800 446 958

Telephone access (metered): +61 7 3107 0210

Online access: http://services.choruscall.com/links/pharmaxis111024.html